Incannex Capital Raising Presentation
• Incannex is undertaking an institutional Placement of approximately $13 million at 0.205 per share • Each share issued under… Read more
• Incannex is undertaking an institutional Placement of approximately $13 million at 0.205 per share • Each share issued under… Read more
An offer of one option for no additional consideration (Placement Option) for every one Placement Share to be issued to… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to attach the address of the CEO,… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal cannabinoid and psychedelic… Read more
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and… Read more
Highlights: • Incannex has engaged CMAX Clinical Research and Novotech CRO to undertake a bioavailability/bioequivalence (‘BA/BE’) study to assess the… Read more
The R&D Tax Incentive is an Australian Federal Government program under which companies receive cash refunds for eligible research and… Read more
All resolutions put to the Annual General Meeting of Harvest Technology Group Limited (ASX:HTG) (Company) held on Tuesday November 8,… Read more